ClinicalTrials.gg
CompletedNCT05029635Updated May 4, 2026

Phase III Study on HMPL-523 for Treatment of ITP

A Phase 3 interventional study of HMPL-523 and Placebo in Primary Immune Thrombocytopenia (ITP), sponsored by Hutchmed. Completed at 37 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Hutchmed · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
272
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China — 82 open to participants now, 92 under way, 12 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · China.

Enrollment
6th of 167
272 · median 62
Started
2021
with 15 others
Phase 3
39 of 185
7 open now
Registered
76th of 185
by date

Among the 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, this one is the 6th largest by enrollment of the 167 interventional ones that give a count, is one of 16 that started in 2021, is one of 39 in phase 3, and was the 76th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

82 of the 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether HMPL-523 (sovleplenib) is safe and effective in the treatment of chronic Immune Thrombocytopenic Purpura (ITP).

Read the detailed description

This study consists of a double-blind phase (primary study) followed by an open-label phase (sub-study). The double-blind phase(n=188) is a randomized, double-blind, placebo-controlled phase III clinical trial in adult patients with primary ITP to determine whether HMPL-523 (sovleplenib) is safe and effective in the treatment of chronic ITP. The sub-study provides open-label HMPL-523 treatment to assess long-term safety and efficacy. The open-label phase have Cohort1 and Cohort 2. Cohort 1 enrolled patients from primary study who have received double-blind study treatment for 12 weeks with sustained platelet count \<50×10⁹/L or have received double-blind study treatment for 24 weeks. Cohort 2 enrolled primary ITP patients(n=84) with disease duration >3 months.

03

Conditions studied

  • Primary Immune Thrombocytopenia (ITP)

Keywords

  • HMPL-523, sovleplenib, ITP, ESLIM-01
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for double-blind phase:

  1. Voluntary signature of written form;
  2. Male or female aged 18\~75 years;
  3. Performance Status score [ (ECOG) score] 0\~1;
  4. Having been diagnosed as ITP prior to randomization, and duration of disease is more than 6 months;
  5. Intolerance or insufficient response, or recurrence after at least one anti-ITP standard drug therapy;
  6. Patients must have a history of response to previous ITP therapy;
  7. One combined anti-ITP therapy is allowed in this study, however, the following criteria need to be met:

    1. The dose of has been stable for 4 weeks prior to randomization (\<20 mg Prednisone equivalent);
    2. The dose of Danazol has been stable for 3 months prior to randomization;
    3. The dose of (only including Azathioprine, Ciclosporin A, Mycophenolate mofetil) has been stable for 3 months prior to randomization.
  8. The condition is relatively stable; WHO bleeding scale grade is 0-1; no emergency treatment is expected within 2 weeks as judged by investigators.
  9. The laboratory examinations need to meet the following conditions (no treatment for this abnormal variable is given within one week prior to blood collection):

    1. Average count \<30×10\^9 /L (and none > 35×10\^9 /L unless as a result of rescue therapy) from at least 3 qualifying counts;
    2. ≥100 g/L, >1.5×10\^9/L;
    3. Total (TBIL), (ALT) and aspartate aminotransferase (AST) ≤1.5× (ULN);
    4. Serum creatinine concentration ≤1.5×ULN and ≥50 mL/min;
    5. Serum amylase and lipase ≤1.5×ULN;
    6. (INR), activated partial thromboplastin time (APTT) not exceeding 20% of normal range.
  10. Male or female patients of must agree to use effective methods during the study and within 90 days after last dose of study drug, e.g., double barrier contraceptive method, condom, oral or injectable contraceptives, intrauterine device, etc. women (>50 years old and no menses for >1 year) and surgically sterilized women are not subject to this condition.

Exclusion Criteria for double-blind phase:

  1. Evidence on the presence of secondary causes of immune thrombocytopenia;
  2. Clinically serious hemorrhage requiring immediate adjustment of platelet (e.g., hypermenorrhea with significantly decreased hemoglobin);
  3. Clinically symptomatic gastrointestinal hemorrhage within 6 months prior to screening visit (e.g., haematemesis, tarry stool, however, the positive occult blood test without any sign or symptom of gastrointestinal hemorrhage will not be considered as "clinically symptomatic", or hemorrhoids hemorrhage is one exception);
  4. known history of vital organ transplantation or hematopoietic stem cell / bone marrow transplantation;
  5. Has received within 8 weeks prior to Day 1 (baseline visit); or plan for immunization with live vaccine during the study;
  6. Splenectomy within 12 weeks prior to randomization;
  7. Major surgery within 4 weeks prior to the randomization, or plan for major elective surgery during the study;
  8. Previous history of malignant tumors (except for the basal cell carcinoma of skin or cervical carcinoma in situ that have been cured);
  9. History of important arterial / venous embolic disease;
  10. Intracranial hemorrhage within 6 months before screening visit;
  11. History of serious cardiovascular disease (e.g., grade III/IV congestive heart failure, arrhythmia or angina pectoris requiring drug therapy, unstable angina pectoris, intracoronary stent implantation, angioplasty or coronary artery bypass grafting, or ≥450 ms);
  12. Hypertension that can not be controlled with drugs (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg);
  13. Previous history of serious gastrointestinal disease, such as dysphagia, active gastric ulcer, inability to take drugs orally or absorption disorder for oral drugs;
  14. (HIV) infection, or (in case of positive HBsAg or HBcAb, positive HBV DNA needs to be determined), or (positive HCV RNA), or liver cirrhosis;
  15. Significant active infection that is not controlled clinically (e.g., sepsis, pneumonia or abscess), or serious infection within 6 weeks prior to randomization (leading to hospitalization or requiring treatment with antibiotic injections);
  16. Has received rescue therapy for ITP within 2 weeks prior to randomization; Has received the treatment for the objective of increasing platelet within 4 weeks prior to randomization (including but not limited to glucocorticoid, thrombopoietin, thrombopoietin receptor agonist, Cyclosporine A, Mycophenolate mofetil, etc.), except those meeting the inclusion criterion 7;
  17. Having received Rituximab within 14 weeks prior to randomization;
  18. Having received traditional Chinese medicine within 1 week prior to randomization;
  19. Requiring long-term/continuous use of the drugs that may affect platelet function [including but not limited to aspirin, Clopidogrel, ticagrelor, NSAIDs, etc.], or anticoagulants;
  20. Intake of potent inhibitor or inducer, as well as sensitive or narrow therapeutic window substrates of CYP3A, CYP1A2 or CYP2B6 two weeks (three weeks for Hypericum perforatum) or 5 half-lives prior to randomization (whichever is longer);
  21. Having participated in the clinical study for drugs or invasive medical device 4 weeks prior to randomization (or within 5 half-lives of the study drug prior to randomization, whichever is longer);
  22. Having received spleen tyrosine kinase Syk inhibitor (e.g., Fostamatinib) previously;
  23. Known allergy to the active ingredient or of study drug;
  24. Presence of serious psychological or mental disorder;
  25. Alcoholic or drug abuser;
  26. Female patients in pregnancy or breast feeding;
  27. Being unsuitable to participate in this study, as considered by investigators.

Inclusion Criteria for open label phase:

  1. Voluntary signing of the ICF for the sub-study;
  2. Performance status score (ECOG score) 0-1;
  3. Relatively stable disease, WHO bleeding grade 0-1;
  4. Female patients of childbearing potential must agree to use highly effective treatment of contraception from screening until 30 days after discontinuation of study treatment of;
  5. Male patients with fertile female partners must consent to use barrier contraception during the study period and for 30 days after the termination of study treatment.

Exclusion Criteria for open label phase:

  1. History of significant arterial/venous embolic disease;
  2. History of serious cardiovascular disease;
  3. Hypertension uncontrolled by medications;
  4. Known to the active ingredient or excipients of the study drug;
  5. Patients with severe psychological or mental disorders;
  6. Alcoholics or drug abusers;
  7. Female patients who are pregnant and lactating;
  8. Patients who, in the opinion of the investigator, are not suitable for this study.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
272 participants (actual)

Study arms

  • Active comparator
    Drug: HMPL-523

    Primacy study (Randomized, Double-Blind Phase): Eligible subjects receive 300 mg HMPL-523 treatment once daily for 24 weeks. Sub study (Open-label Phase): Eligible subjects receive 300 mg HMPL-523 treatment once daily for 76 weeks after the enrollment of the last patient enrolled in open-label phase.

    Drug: HMPL-523

  • Placebo comparator
    Drug: placebo

    Primacy study (Randomized, Double-Blind Phase): Eligible subjects will receive 300 mg HMPL-523 matched placebo treatment once daily for 24 weeks.

    Drug: Placebo

Interventions

  • HMPL-523(300mg PO QD)

    Also known as: Sovleplenib

  • DrugPlacebo

    Placebo(300mg PO QD)

06

What researchers measure

Primary outcomes

  1. the durable response rate in the primary study

    Platelet count ≥50×10\^9 /L on at least 4 of 6 scheduled visits of Week14-Week24 in the primary study

    Time frame: treatment period Week14-Week24

Secondary outcomes

  1. the overall response rate in the primary study

    At least one platelet count ≥50×10\^9 /L (except that induced by the rescue therapy) in the 24-week double-blind treatment period

    Time frame: treatment period Week1-Week24 in the primary study

  2. Incidence of treatment emergent adverse events

    Adverse events classified according to NCI CTCAE version 5.0

    Time frame: treatment period Week1-Week24 in the primary study

  3. Plasma concentration at steady state 2 hours post dose (C2h,ss)

    Plasma concentration of HMPL-523 and its main metabolites at steady state 2 hours post dose (C2h,ss) will be determined.

    Time frame: treatment period Week1-Week24 in the primary study

  4. Plasma concentration at steady state 2 hours post dose (C4h,ss)

    Plasma concentration of HMPL-523 and its main metabolites at steady state 4 hours post dose (C4h,ss) will be determined.

    Time frame: treatment period Week1-Week24 in the primary study

  5. Plasma concentration at steady-state trough concentration (Cmin,ss)

    Plasma concentration of HMPL-523 and its main metabolites at steady-state trough concentration (Cmin,ss) will be determined.

    Time frame: treatment period Week1-Week24 in the primary study

07

Study locations

37 sites
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
  • The First Affiliated hospital of USTC
    Hefei, Anhui, China
  • Beijing Chaoyang Hospital of Capital Medical University
    Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality, China
  • People's Hospital of Peking University
    Beijing, Beijing Municipality, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian, China
  • Lanzhou University Second Hospital
    Lanzhou, Gansu, China
  • Guangdong General Hospital
    Guangzhou, Guangdong, China
  • Southern Hospital of Southern Medical University
    Guangzhou, Guangdong, China
  • The Second People's Hospital Of Shenzhen
    Shenzhen, Guangdong, China
  • The First Affiliated Hospital Of GuangXi Medical University
    Nanning, Guangxi, China
  • The First Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • Affiliated Hospital of North China University of Technology
    Tangshan, Hebei, China
  • First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
  • Union Hospital affiliated to Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • Xiangyang Central Hospital
    Xiangyang, Hubei, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • Xiangya Hospital Central South University
    Changsha, Hunan, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning, China
  • The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University
    Huai'an, Nanjing Province, China
  • Qinghai province people's hospital
    Xining, Qinghai, China
  • Jinan Central Hospital Affilated to Sandong University
    Jinan, Shandong, China
  • LiaoCheng People's Hospital
    Liaocheng, Shandong, China
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong, China
  • Jinshan Hospital Affiliated To Fudan University
    Shanghai, Shanghai Municipality, China
  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality, China
  • Heping Hospital Affiliated to Changzhi Medical College
    Changzhi, Shanxi, China
  • The second hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
  • Shanxi Provincial People's Hospital
    Xi’an, Shanxi, China
  • West China Hospital,Sichuan University
    Chengdu, Sichuan, China
  • The First Affilicated Hospital of Xinjiang Medical University
    Ürümqi, The Xinjiang Uygur Autonomous Region, China
  • Blood Institute of the Chinese Academy of Medical Sciences
    Tianjin, Tianjin Municipality, China
  • The second Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan, China
  • Zhejiang Provincial Hospital of Chinese Medicine
    Hangzhou, Zejiang Province, China
08

References and documents

Publications

  • Hu Y, Liu X, Zhou H, Wang S, Huang R, Wang Y, Du X, Sun J, Zhou Z, Yan Z, Chen W, Wang W, Liu Q, Zeng Q, Gong Y, Yin J, Shen X, Ye B, Chen Y, Xu Y, Sun H, Cheng Y, Liu Z, Wang C, Yuan G, Zhang X, Li X, Cheng P, Guo X, Jiang Z, Yang F, Yang L, Luo C, Xiao T, Fu S, Yin H, Guo X, Xu Q, Fan S, Shi MM, Su W, Mei H, Yang R. Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Haematol. 2024 Aug;11(8):e567-e579. doi: 10.1016/S2352-3026(24)00139-X. Epub 2024 Jun 14. PubMed 38885672 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in May 2025, 42 months.

Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 42 months is above that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2021
First posted
Aug 31, 2021
StartActual
Oct 27, 2021
Primary completionActual
May 16, 2025
CompletionActual
Sep 18, 2025
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05029635
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Aug 31, 2021
Start date
Oct 27, 2021
Primary completion
May 16, 2025
Completion
Sep 18, 2025
Last update
May 4, 2026

Study contacts

Renchi Yang, professor
principal investigator · offices director

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sovleplenib

Start the discussion